TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18779885
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment alone
Study: 18779885
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment with occlusive dressings (hydrocolloid)
Study: 21772226
Drug: Sucralose (control)
Normalized name: Sucralose
DrugBank: Sucralose (DB15049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (control) in 250 mL of water with or without TVV
Study: 19521532
Drug: Human and
Normalized name: cultured skin substitute,human and bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human and bovine PZQ treatment
Study: 17143493
Drug: UFT (5-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (5-8 mg/kg/day)
Study: 17143493
Drug: UFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT plus CPA (1 mg/kg/one day interval)
Study: 15551193
Drug: Zotepine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (average dose of 131 +/- 49 mg/day)
Study: 14526301
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 75 microg every 4 hours as needed
Study: 7640146
Drug: Dothiepin 75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin 75‐150 mg
Study: 30528472
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg
Study: 2501094
Drug: GTN patch
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN patch (7.5 mg GTN)
Study: 9060881
Drug: L-arginine hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine hydrochloride, 8.4 g/day orally for 2 weeks
Study: 9060881
Drug: L-arginine hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine hydrochloride, 8.4 g/day orally after 2 weeks of treatment
Study: 23772999
Drug: Lindane lotion
Normalized name: Lindane Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindane lotion 1% (two applications with a 1-week interval)
Study: 20100317
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimized treatment according to European Society of Cardiology guidelines)
Study: 2645013
Drug: Pre-operative antibiotics
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative antibiotics (group P): 3 intravenous doses of 500 mg metronidazole plus 1 g cephazolin.
Study: 2645013
Drug: Intra-operative antibiotics
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative antibiotics (group T): 3 intravenous doses of 500 mg metronidazole plus 1 g cephazolin.
Study: 30772014
Drug: Insulin-sensitizing (IS)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-sensitizing (IS) therapy
Study: 30772014
Drug: Insulin-providing (IP)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-providing (IP) therapy
Study: 15631531
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy (lovastatin or pravastatin 10, 20 or 40 mg, simvastatin or atorvastatin 10, 20, 40 or 80 mg)
Study: 8037485
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day) for 2 years
Study: 8037485
Drug: No tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tamoxifen administration
Study: 2564753
Drug: Flumazenil (0.6-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.6-1.0 mg iv)
Study: 22980542
Drug: Bone morphogenetic
Normalized name: Bone morphogenetic proteins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel at a concentration of 250 μg ml(‐1)
Study: 22980542
Drug: Bone morphogenetic
Normalized name: Bone morphogenetic proteins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel at a concentration of 50 μg ml(‐1)
Study: 16630937
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablet 75,000 SQ-T
Study: 16630937
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablet 75,000 SQ-T (subgroup analysis)
Study: 9578184
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg)
Study: 2322635
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam SR tablet while fasting
Study: 2322635
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam SR tablet immediately after a standardized breakfast
Study: 377897
Drug: PGE2-gel (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2-gel (0.25 mg PGE2)
Study: 16766594
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic antifungal prophylaxis (arm B)
Study: 9257763
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of isepamicin (1-g dose)
Study: 9257763
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of isepamicin (1-g dose)
Study: 9257763
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of isepamicin
Study: 9257763
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of isepamicin
Study: 9257763
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion and intramuscular injection of isepamicin
Study: 2433016
Drug: Cisplatin (CDDP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP), vincristine, and bleomycin or CDDP and 5‐fluorouracil (5‐FU) infusion
Study: 2433016
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and 5‐FU infusion combination
Study: 24936727
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day omega-3 soft gels
Study: 18306150
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with antipsychotic drugs for 4 weeks
Study: 8017358
Drug: enprostil 35
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enprostil 35 micrograms twice daily
Study: 8017358
Drug: enprostil 35
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enprostil 35 micrograms three times daily
Study: 2598950
Drug: sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sustained-release diltiazem (diltiazem-SR) 120 mg b.i.d.
Study: 2598950
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg b.i.d.
Study: 15679130
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg/kg
Study: 31823556
Drug: PRP injection
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP injection group (group A)
Study: 26059497
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (Fluor Protector; FV group) applied biannually plus biannual treatments with placebo varnish
Study: 11586996
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg for 7 days
Study: 11586996
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg for 7 days
Study: 9832348
Drug: Sertraline 50-150
Normalized name: sertraline 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-150 mg
Study: 9832348
Drug: Amitriptyline 75-225
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75-225 mg
Study: 2643773
Drug: BM 13,177
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM 13,177 (thromboxane-receptor antagonist)
Study: 2643773
Drug: Aspirin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (20 mg twice daily for four weeks)
Study: 30665608
Drug: MI-CBT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-CBT + CC
Study: 19476198
Drug: Behavioral counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral counseling and a novel medication
Study: 2491863
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc (50 mg)
Study: 31845316
Drug: Intrathecal bupivacaine/morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine/morphine (12.5 mg bupivacaine/300 μg morphine)
Study: 31653138
Drug: Filial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filial therapy
Study: 17958901
Drug: PG-116800 50
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-116800 50 mg, taken twice daily for 12 months
Study: 17958901
Drug: PG-116800 100
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-116800 100 mg, taken twice daily for 12 months
Study: 17958901
Drug: PG-116800 200
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-116800 200 mg, taken twice daily for 12 months
Study: 17958901
Drug: PG-116800 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-116800 (200 mg group)
Study: 17958901
Drug: PG-116800 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-116800 (two highest dose groups)
Study: 3755516
Drug: Phenobarbital administered
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital administered to mothers in doses sufficient to achieve blood levels of 15 to 40 micrograms/mL
Study: 3755516
Drug: No antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antenatal treatment (control group)
Study: 3755516
Drug: Phenobarbital administered
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital administered to mothers
Study: 25169488
Drug: single chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: single chemotherapy
Study: 11978276
Drug: Traditional parenteral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional parenteral analgesia (parenteral morphine via PCA pump with basal dose of 0.5 mg/h and PCA dose of 1 mg)
Study: 29436320
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitisation and Reprocessing (EMDR) therapy
Study: 30009473
Drug: Proenkephalin (PENK)
Normalized name: [met5]-enkephalin
DrugBank: Metenkefalin (DB12668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proenkephalin (PENK) measured at baseline and on day 1 after contrast media administration
Study: 23591789
Drug: DA+GO (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA+GO (daunorubicin 45 mg/m(2) on days 1-3, cytarabine 100 mg/m(2) continuous infusion on days 1-7, GO 6 mg/m(2) on day 4)
Study: 23591789
Drug: DA (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA (daunorubicin 60 mg/m(2) on days 1-3, cytarabine alone)
Study: 23591789
Drug: DA+GO (postconsolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA+GO (postconsolidation therapy with 3 doses of GO 5 mg/m(2) every 28 days)
Study: 23591789
Drug: DA (postconsolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA (postconsolidation therapy with no additional therapy)
Study: 18378631
Drug: Glimepiride, 1
Normalized name: Glimepiride, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride, 1 to 4 mg
Study: 18378631
Drug: Pioglitazone, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone, 15 to 45 mg
Study: 12798527
Drug: Phytoestrogens (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens (tablets containing 114 mg of isoflavonoids)
Study: 9758289
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid
Study: 2528295
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant DNA hepatitis B vaccine (20 micrograms)
Study: 2528295
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant DNA hepatitis B vaccine (40 micrograms)
Study: 2528295
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant DNA hepatitis B vaccine (zero, one, two, six months schedule)
Study: 2528295
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant DNA hepatitis B vaccine (zero, one, two, twelve months schedule)
Study: 391629
Drug: Compound analgesic
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound analgesic with chlormezanone
Study: 391629
Drug: Compound analgesic
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound analgesic (placebo-controlled)
Study: 30839428
Drug: Simulated opioid-tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated opioid-tapering advice
Study: 28781336
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS), twice a day, for three months
Study: 28781336
Drug: Short-acting β2-adrenoreceptor
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β2-adrenoreceptor agonist (SABA), inhalation only if necessary
Study: 25935057
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid and HBO (group 1)
Study: 25935057
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid (ITS) with systemic steroid and HBO (group 2)
Study: 16449425
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Stress Management (CBSM) + Medication Adherence Training (MAT)
Study: 15895421
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day)
Study: 17037821
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg/day)
Study: 3581104
Drug: Carmustine, hydroxyurea,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carmustine, hydroxyurea, and dacarbazine chemotherapy
Study: 3581104
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no chemotherapy)
Study: 3581104
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment and control arms
Study: 26173655
Drug: Caffeine (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6.0 mg/kg body mass)
Study: 24118269
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) up to 180 mg/day
Study: 12800128
Drug: Behavioral counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral counseling and pharmacotherapy
Study: 1853462
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (GaAlAs, 830 nm, continuous)
Study: 6401928
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium 4% ophthalmic solution
Study: 29454227
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with placebo
Study: 22047637
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy sessions with significant others present
Study: 22047637
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy sessions without significant others (implied control)
Study: 11311658
Drug: Taxanes (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxanes (paclitaxel and docetaxel) with concurrent radiotherapy
Study: 8046313
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation with a target INR of 2.0-2.85
Study: 26715479
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 2.5 µg (R2.5)
Study: 26715479
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 5 µg (R5)
Study: 9296232
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 1 g at infusate concentrations of 1 mg/mL
Study: 9296232
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 1 g at infusate concentrations of 2 mg/mL
Study: 9296232
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 1 g at infusate concentrations of 4 mg/mL
Study: 9296232
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 1 g at infusate concentrations of 5 mg/mL
Study: 2947615
Drug: Buccal flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal flap method (Rehrmann, 1936)
Study: 27482615
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (ALN) 70 mg weekly
Study: 25842457
Drug: Test gel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test gel (TG) - 5% sodium fluoride, 5% potassium oxalate, 10% strontium chloride
Study: 25945764
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (PG)
Study: 2082483
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg aspirin combined with 400 mg dipyridamole
Study: 2567792
Drug: Standard anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulant therapy
Study: 17070365
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil
Study: 30251330
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin
Study: 26438038
Drug: 0.12 %
Normalized name: Oris 0.12 % Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 % I‐C nasal spray, four times daily for four to ten days
Study: 26438038
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (NaCl 0.5 %), four times daily for four to ten days
Study: 24279305
Drug: Minocycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (200 mg/day orally) added to regular antipsychotic medications for 12 weeks
Study: 24279305
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive compound identical in appearance to minocycline)
Study: 22081616
Drug: L. barbarum
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. barbarum (120 ml)
Study: 22081616
Drug: L. barbarum
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. barbarum (120 ml daily for 14 days)
Study: 15880608
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (peginterferon and lamivudine)
Study: 14624818
Drug: Group comprehensive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group comprehensive cognitive behavioral therapy (CCBT)
Study: 14624818
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FLU and PLA
Study: 2058823
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg/kg i.v. induction and 3-5 mg/kg per hour i.v. maintenance
Study: 2058823
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg/kg i.v. induction and isoflurane 0.4-0.8 vol.% maintenance
Study: 2058823
Drug: Etomidate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2 mg/kg i.v. induction and flunitrazepam 0.005-0.01 mg/kg i.v. and fentanyl 0.0025-0.005 mg/kg i.v. bolus injections every 20-30 min maintenance
Study: 6286118
Drug: PIVN-associated chemotherapy
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIVN-associated chemotherapy
Study: 6276949
Drug: Chemotherapy control
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy control group
Study: 6286118
Drug: PIVN-associated chemotherapy
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIVN-associated chemotherapy and chemotherapy control group
Study: 22966839
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (WBV) for 2 weeks, six 15-min sessions, 2 mm amplitude, 12 Hz frequency
Study: 22966839
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (WBV)
Study: 17470020
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (275 mg daily for 6 weeks)